Handelsavisen
prelaunch
Companies Healthcare 600763.SS
60
600763.SS Shanghai Stock Exchange Healthcare Facilities & Services

Topchoice Medical Co Inc

¥36,63
Open in Charts → Attach watcher ⌖
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
24,3 %
ROE
11,9 %
Net margin
17,2 %
Debt / equity
0,26
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Topchoice Medical Co Inc is a pharmaceutical company that generates revenue primarily through the production and sale of medical products and services.

Business. Topchoice Medical Co Inc (600763.SS) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm operates within the Healthcare Facilities & Services industry, generating revenue through service-based models. Headquartered in China, the company is listed on the Shanghai Stock Exchange. Specific operating segments and geographic breakdowns are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
HOLD10 analysts
5 buy3 hold2 sell
Avg 12m price target44,81

Analyst recommendations

10 analysts · consensus Hold
Buy5
Hold3
Sell2
12-month price target
44,81
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
10 analysts · indicative
Ownership
not yet wired
Profitability
11,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 600763.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 600763.SS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Topchoice Medical Co Inc (600763.SS) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm operates within the Healthcare Facilities & Services industry, generating revenue through service-based models. Headquartered in China, the company is listed on the Shanghai Stock Exchange. Specific operating segments and geographic breakdowns are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    Topchoice Medical Co Inc maintains a strong capital structure with a debt-to-equity ratio of 0.26, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.49, suggesting it has sufficient short-term assets to cover its short-term liabilities, but not in excess. Free cash flow stands at 365.81 million CNY, which provides flexibility for reinvestment or shareholder returns.

    Profitability metrics show that the company is performing well relative to industry standards. Return on equity (ROE) is 11.86%, and return on assets (ROA) is 8.31%, both of which are strong indicators of efficient use of equity and assets. These figures suggest that the company is generating solid returns for its shareholders and effectively utilizing its asset base to generate income.

    The company's revenue is primarily concentrated in the pharmaceutical segment, with no disclosed geographic breakdown. This concentration may expose the company to specific market risks, such as regulatory changes or shifts in demand within the pharmaceutical industry. However, the lack of geographic diversification data makes it difficult to assess the extent of such risks.

    Looking ahead, the company is expected to maintain a stable growth trajectory. Analysts have provided a mean price target of 44.81 CNY, with a median of 45.63 CNY, indicating a generally positive outlook. The mean recommendation of 2.60 suggests a mixed sentiment among analysts, with a slight lean towards a buy rating. The company's revenue history and current financial health support this outlook.

    Risk factors for the company include a medium liquidity risk and a low dilution risk. The company has a negative net cash position after subtracting total debt, which could affect its ability to meet short-term obligations. However, the low dilution risk indicates that the company is not expected to issue additional shares in the near term, preserving shareholder value.

    Recent events and filings have not been disclosed in the provided data, so it is unclear if there have been any significant developments that could impact the company's operations or financial performance. Investors should monitor any new filings or announcements for potential insights into the company's future direction.

    Key takeaways
    • Topchoice Medical Co Inc has a strong ROE of 11.86% and ROA of 8.31%, indicating efficient use of equity and assets.
    • The company's debt-to-equity ratio of 0.26 suggests a conservative capital structure with low debt reliance.
    • Analysts have a generally positive outlook, with a mean price target of 44.81 CNY and a median of 45.63 CNY.
    • The company's liquidity position is medium, with a current ratio of 1.49, indicating adequate but not excessive short-term liquidity.
    • The company has a low dilution risk, suggesting no immediate threat to shareholder value from new share issuance.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥36,63
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    ¥4.23B
    Net cash
    -¥1.11B
    Current ratio
    1.5
    Debt / equity
    0.3
    ROA
    8.3%
    ROE
    11.9%
    Cash conversion
    162.0%
    CapEx / revenue
    -8.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    1,27
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    10
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-25 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate1,27
    Revenueno estimateno estimate3,3B CNY
    Operating incomeno estimateno estimate776,6M CNY
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution10 analysts
    Strong buy2
    Buy3
    Hold3
    Sell1
    Strong sell1
    12-month price target¥44,81 · Median ¥45,63
    Low ¥30,00High ¥55,88
    Operating income · consensus776,6M CNY
    EPS surprise
    −11,7 %
    reported vs consensus · miss
    Revenue surprise
    −10,9 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low¥30,00
    Mean¥44,81
    Median¥45,63
    High¥55,88
    Spot¥36,63
    +22.3 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin24,3 %Above P75
    Net Margin17,2 %Above P75
    ROE11,9 %Above median
    Capex / Rev-8,5 %Below median
    D/E0,26Above median
    Cash Conv1,62Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Topchoice Medical Co Inc Market data — financials · 2026-05-27
    • Topchoice Medical Co Inc Market data — analyst estimates · 2026-05-27
    • Topchoice Medical Co Inc Market data — ESG · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    600763.SSCanonical
    Shanghai Stock Exchange · CNY

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage